SETD2 and nonpapillary renal cell carcinoma: In light of the observation that SETD2 deficiency gave rise to enhanced SM content, which is strongly related to cancer initiation, growth, and immune evasion22, we were prompted to test whether SM synthesis inhibitors can confer protective effects against SETD2-loss-induced PKD-ccRCC transition in vivo.